Moreover, Zhang J. et al. [36] evaluated the diagnostic performance of [68Ga]PSMA PET/CT in the detection of suspected PCa in patients with PSA from 0.4 to 50 ng/mL, comparing PET/CT efficacy with that derived from the European Randomized Study of Screening for Prostate Cancer Risk Calculator Version 3 (ERSPC-RC3) and Prostate Cancer Prevention Trial Risk Calculator (PCPT-RC) nomograms. This evidence concerns the gene FOLH1 and prostate carcinoma.